Description

DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug

Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the drug as a major agent for treating heart failure.

New hypertension cases halved with community-wide salt substitution

Social marketing principles achieved near-universal salt replacement, village by village, in rural Peru.

Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD

Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.

In PAD, dropping statins ups death risk 43%

Statin adherence saves lives in peripheral arterial disease.